Antimicrobial Phage Enzymes for Healthcare Disinfection

Abstract

Hospital-acquired infections (HAIs) continue to pose a significant threat to patient safety worldwide, with antimicrobial resistance (AMR) compounding the challenge of effective environmental disinfection. Antimicrobial phage enzymes, particularly endolysins and depolymerases, have emerged as innovative biocidal agents with potential for targeted microbial eradication on healthcare surfaces. This review synthesizes current evidence on the mechanism, clinical relevance, efficacy, and practical application of phage-derived enzymes for healthcare disinfection, providing a comprehensive perspective for clinicians and infection control specialists.

Introduction

Infection prevention and control remain critical pillars of patient safety in modern healthcare settings. Traditional disinfectants, while effective, face limitations such as incomplete eradication of pathogens, toxicity, material incompatibility, and promotion of antimicrobial resistance. The increasing prevalence of multidrug-resistant organisms (MDROs) necessitates alternative approaches. Bacteriophage-derived enzymes, including endolysins and depolymerases, represent a novel class of antimicrobials with high specificity and potent lytic activity against bacterial pathogens. Their application as surface disinfectants in healthcare environments is an evolving area of scientific inquiry and clinical interest.

Epidemiology / Disease Burden

HAIs impact millions globally each year, with the World Health Organization estimating hundreds of thousands of deaths annually due to infections acquired in healthcare facilities. Common pathogens include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and Clostridioides difficile, all of which contribute to prolonged hospital stays, increased healthcare costs, and higher morbidity and mortality. Environmental reservoirs, such as bed rails, medical equipment, and high-touch surfaces, play a critical role in the transmission of these pathogens, highlighting the urgent need for effective disinfection strategies.

Pathophysiology

Bacteriophage enzymes, particularly endolysins, hydrolyze peptidoglycan components of bacterial cell walls, leading to rapid cell lysis. Unlike traditional antibiotics, which require bacterial metabolism or growth, endolysins exert direct enzymatic action, making them effective even against dormant or biofilm-embedded bacteria. Depolymerases target extracellular polysaccharides, disrupting biofilm integrity and enhancing susceptibility to other antimicrobial agents. This dual mechanism not only eradicates planktonic bacteria but also addresses the persistent challenge of biofilm-associated contamination on healthcare surfaces.

Risk Factors

Environmental contamination risk increases with high patient turnover, inadequate cleaning protocols, presence of MDROs, and frequent use of invasive devices. Immunocompromised patients, intensive care settings, and areas with frequent antibiotic usage are particularly vulnerable. The persistence of bacterial biofilms on surfaces further exacerbates the risk of transmission, as biofilms confer resistance to conventional disinfectants and facilitate chronic contamination cycles.

Clinical Features

While antimicrobial phage enzymes do not cause clinical symptoms, their clinical utility lies in reducing the microbial load on surfaces and interrupting the chain of infection. Studies have demonstrated significant reductions in colony-forming units (CFUs) of MRSA, VRE, and Pseudomonas aeruginosa following application of phage-derived enzymatic formulations. The ability to disrupt biofilms is a critical advantage, as these structures are often impervious to routine cleaning and chemical disinfectants.

Diagnosis

Assessment of surface contamination in healthcare settings typically involves quantitative and qualitative culture-based methods, ATP bioluminescence assays, and molecular techniques such as qPCR for rapid pathogen detection. The efficacy of phage enzymes as disinfectants can be evaluated through pre- and post-application microbial load measurements, biofilm disruption assays, and surface sampling in clinical environments. Ongoing surveillance and environmental monitoring are essential to gauge the long-term impact of integrating phage enzymes into infection control protocols.

Treatment & Management

The application of phage enzymes for healthcare disinfection involves formulation into sprays, wipes, or coatings that can be applied to various surfaces. Protocols vary according to the targeted pathogens, environmental conditions, and compatibility with existing cleaning regimens. Integration with current disinfection protocols requires consideration of enzyme stability, spectrum of activity, and potential interactions with chemical agents. Pilot studies have reported successful reduction of MDROs and biofilms in intensive care units and operating theaters without adverse material effects or toxicity concerns.

Recent Advances / Emerging Therapies

Recent advances include engineered endolysins with broadened host range, thermostable formulations for prolonged activity, and fusion proteins combining lytic and biofilm-degrading functions. Novel delivery systems, such as encapsulation in nanoparticles or immobilization on surface coatings, enhance enzyme stability and sustained release. Clinical trials are underway to evaluate the effectiveness of phage enzymes in real-world hospital environments, with preliminary results demonstrating superior efficacy compared to traditional disinfectants, especially against recalcitrant biofilms and MDROs. Regulatory agencies are beginning to issue guidance on the safe use of biological disinfectants, paving the way for clinical adoption.

Guideline Recommendations

While formal guidelines for phage enzyme-based disinfection are still evolving, leading infection control bodies emphasize the importance of multi-modal approaches to environmental hygiene. The Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) recommend integrating novel technologies with established cleaning protocols, particularly in high-risk settings. Early adopter institutions report positive outcomes when phage enzymes are used as adjuncts rather than replacements for conventional disinfectants. Ongoing research and consensus-building efforts are expected to inform evidence-based recommendations for widespread clinical use.

Conclusion

Antimicrobial phage enzymes represent a promising frontier in healthcare disinfection, offering targeted lytic activity, biofilm disruption, and reduced risk of resistance development. Their incorporation into environmental hygiene protocols may significantly reduce HAIs and improve patient outcomes, particularly in the era of rising antimicrobial resistance. Continued research, clinical trials, and guideline development are essential to fully realize the potential of phage enzymes as adjuncts or alternatives to traditional chemical disinfectants in healthcare settings.